Bonito Biosciences and DaltonTx Collaborate on Precision Delivery for Oligotherapeutics

Bonito Biosciences and DaltonTx agreed to collaborate to help advance next-generation precision delivery systems for Bonito’s oligotherapeutic medicines. The collaboration will initially focus on delivery to the central nervous system, combining Bonito’s functional delivery data engine and ligand discovery platform with DaltonTx’s AI systems which are designed to iteratively model, predict, and optimize precision delivery biology.

Together, the companies will work to identify, optimize, and advance delivery ligands for conjugated oligotherapeutic payloads, including novel bispecific approaches for targeted CNS delivery, according to officials at both firms.

Through its functional selection platform, Bonito screens hundreds of billions of encoded ligands against complex cellular delivery phenotypes, explained a Bonito spokesperson, adding that these datasets–physically generated and directly tested on cell systems of interest– capture high-dimensional information related to receptor engagement and cellular delivery.

DaltonTx will apply its AI capabilities to model these data and to work on accelerating the design and optimization of next-generation delivery ligands through structural prediction, affinity mapping, and developability analysis. Together, the companies aim to establish an iterative learning loop for the rapid discovery of precision delivery systems for conjugated oligotherapeutics, noted Richard Wagner, CEO of Bonito.

“This collaboration brings together two highly complementary capabilities: Bonito’s ability to generate uniquely rich functional delivery data at massive scale and DaltonTx’s deep expertise in adaptive AI systems for molecular design and optimization,” he continued. “We believe precision delivery is fundamentally a data and prediction problem. By combining closed-loop functional screening with AI-driven design, we aim to accelerate the discovery of delivery systems capable of reaching tissues and cell types that have historically remained inaccessible to oligotherapeutics.”

“AI systems are only as powerful as the quality and dimensionality of the underlying biological data,” pointed out Garry Pairaudeau, CEO and co-founder of DaltonTx. “Bonito has built a uniquely differentiated platform for generating functional delivery datasets at extraordinary scale. Combining these data with DaltonTx’s agentic AI platform, which integrates AI, human expertise, and experimental data into one continuous learning engine, has the potential to significantly accelerate the discovery of next-generation delivery systems for conjugated oligotherapeutics.”

The post Bonito Biosciences and DaltonTx Collaborate on Precision Delivery for Oligotherapeutics appeared first on GEN - Genetic Engineering and Biotechnology News.